doi:10.16139/j.1007-9610.2019.05.009

[1] 陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志,2017,55(2):99-103.
[2] Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[3] Paik S, Shak S, Tang G, et al.A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med,2004,351(27):2817-2826.
[4] van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med,2002,347(25):1999-2009.
[5] Dubsky P, Brase JC, Jakesz R, et al.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients[J]. Br J Cancer,2013,109(12):2959-2964.
[6] Filipits M, Nielsen TO, Rudas M, et al.The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer[J]. Clin Cancer Res,2014,20(5):1298-1305.
[7] Paik S, Tang G, Shak S, et al.Gene expression and be-nefit of chemotherapy in women with node-negative, estro-gen receptor-positive breast cancer[J]. J Clin Oncol,2006, 24(23):3726-3734.
[8] Sparano JA, Gray RJ, Makower DF, et al.Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med,2015,373(21):2005-2014.
[9] Sparano JA, Gray RJ, Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.
[10] Sparano JA, Gray RJ, Ravdin PM, et al.Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med,2019,380(25):2395-2405.
[11] Albain KS, Barlow WE, Shak S, et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol,2010,11(1):55-65.
[12] Nitz U, Gluz O, Clemens M, et al.West German Study PlanB Trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of do-cetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol,2019,37(10):799-808.
[13] Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.
[14] Krop I, Ismaila N, Andre F, et al.Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of Clinical Oncology Clinical Practice Guideline focused update[J]. J Clin Oncol,2017,35(24):2838-2847.
[15] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846.
[16] Ma XJ, Wang Z, Ryan PD, et al.A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen[J]. Cancer Cell,2004,5(6):607-616.
[17] Sgroi DC, Sestak I, Cuzick J, et al.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population[J]. Lancet Oncol,2013,14(11):1067-1076.
[18] Sestak I, Buus R, Cuzick J, et al.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553.
[19] Carey LA, Berry DA, Cirrincione CT, et al.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase Ⅲ trial of paclitaxel plus trastuzumab with or without lapatinib[J]. J Clin Oncol,2016,34(6):542-549.
[20] Perez EA, Ballman KV, Mashadi-Hossein A, et al. Intrinsic subtype and therapeutic response among HER2-positive breaty st tumors from the NCCTG (Alliance) N9831 trial[J]. J Natl Cancer Inst,2016,28:109(2). pii: djw207.
[21] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med,2017,377(2):122-131.
[22] Krop I, Paulson JN, Campbell C, et al.Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab(P) in HER2+ breast cancer(BC): Biomarker analysis of the APHINITY trial[J]. J Clin Oncol,2019, 37(15S):37S.
[23] Lehmann BD, Bauer JA, Chen X, et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-2767.
[24] Jiang YZ, Ma D, Suo C, et al.Genomic and transcripto-mic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell,2019,35(3):428-440.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[2]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[4]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[5]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[9]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[10]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[11]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[12]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[13]	LIU Miao, SHEN Yan, FU Xiaohong, HU Jiaojiao, CHEN Qingqing, YING Tao. A comparative study on breast cancer between smaller and larger diameters using conventional ultrasound and contrast-enhanced ultrasound [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 229-233.
[14]	CHEN Yuanyuan, YE Xin, TANG Yongzhe, WANG Jie, HE Qi. Prognosis of invasive micropapillary carcinoma versus invasive ductal carcinoma of the breast: a comparative analysis after propensity score matching [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 353-360.
[15]	CHEN Xiaosong, LI Shuai, WU Jiayi, HUANG Ou, CHAI Weimin, YAO Jiejie, ZHU Ying, XU Chen, CHEN Jiayi, QU Qing, FEI Xiaochun, DING Xiaoyi, LIN Lin, ZHANG Nan, FANG Qiong, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei. Diagnosis, treatment and survival of breast cancer patients in single large hospital: a 10-year analysis [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 149-158.